                </a></li></ul></div><p><strong>Figure 1.  <span>Combination therapy of Etanercept with mycobacterial heat shock protein 60 (HSP60) 180-188 led to significant reduction of Adjuvant Arthritis (AA).</span></strong></p><a id="article1.body1.sec3.sec1.fig1.caption1.p1" name="article1.body1.sec3.sec1.fig1.caption1.p1"></a><p>Arthritis was induced on day 0 with Complete Freund's Adjuvant (CFA).</p>
<a id="article1.body1.sec3.sec1.fig1.caption1.p2" name="article1.body1.sec3.sec1.fig1.caption1.p2"></a><p>On day 9, rats were randomly divided into five treatment groups: three doses of Etanercept s.c. on day 9, 11, 13 (equivalent to a full course of Etanercept treatment); one dose of Etanercept on day 9; four doses of mycobacterial HSP60 peptide 180-188 on day 10, 13, 16, 19; combination treatment of one dose of Etanercept s.c. on day 9 followed by 180-188 nasally on day 10, 13, 16, 19; or no treatment (PBS).</p>
<a id="article1.body1.sec3.sec1.fig1.caption1.p3" name="article1.body1.sec3.sec1.fig1.caption1.p3"></a><p>Arthritis scores were assessed every other day from day 8 onward.</p>
<a id="article1.body1.sec3.sec1.fig1.caption1.p4" name="article1.body1.sec3.sec1.fig1.caption1.p4"></a><p>N = 15â€“18 rats per treatment group. Shown are mean arthritis scores.</p>
<span>THISISTHEEND
